X

Focusing Payment and Delivery on Patients

Allyson Funk   |     May 15, 2015   |   SHARE THIS

PhRMA_Value_Collaborative_Reversed.jpg
As the way we pay for and deliver health care in the United States evolves, we’ve talked about the importance of patient engagement in the process and ensuring that our system doesn’t treat patients like an average, but as individuals.

Not surprisingly, patient advocacy groups are in agreement. A story in Inside Health Policy last week highlights the efforts of 60 groups, including the Alliance for Aging Research, Association of Community Cancer Centers, Partnership to Improve Patient Care and others, to ensure the Department of Health and Human Services (HHS) puts patients at the forefront of the development of payment reforms and models. (More on HHS’ initiative here and here.) The groups stress that doing so will open doors for more individualized treatment that will lead to improved health outcomes.

We recently talked with several cancer advocates to get their perspectives in our Conversations forum on payment and delivery reform.  Linda House, president of the Cancer Support Community, asks, “What is the experience of the patient? Are the measures and the payments being attached to what patients define as value?  A lot of times they may not be aligned with what policymakers define as value.”

Payment

PhRMA believes payment reform should increase the benefit individual patients receive from their health care, while also ensuring they are not forgotten in the process. Our key principles outline best practices for payment model design, which should support continued biomedical progress, improve the value of patient care and protect access to high-quality health care.

We all need to work together to put forth models that improve the patient experience on a case-by-case basis with an emphasis on quality over quantity. No two patients are alike, so their care shouldn’t be treated that way either. 

Allyson Funk

Allyson Funk Ally is a former senior director of public affairs at PhRMA focused on advocacy issues for the biopharmaceutical industry. Her expertise includes Medicare, Medicaid, 340B, health reform and more. Prior to PhRMA, her experience included leading health communications for a large membership organization, supporting public affairs clients and working for the governor of Louisiana.

Topics: Cancer, Alternative Payment Models, Value-Driven Health Care, The Value Collaborative

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates